165 related articles for article (PubMed ID: 1417016)
1. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
[TBL] [Abstract][Full Text] [Related]
2. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661
[TBL] [Abstract][Full Text] [Related]
3. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (first report)--preclinical study of GAT assay kit and clinical study of normal level].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):271-7. PubMed ID: 8434966
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
Ito K; Udagawa Y; Nozawa S
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
[TBL] [Abstract][Full Text] [Related]
6. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
7. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
[TBL] [Abstract][Full Text] [Related]
8. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
10. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
Inaba N; Okajima Y; Ota Y; Fukazawa I; Yamaguchi T; Sato N; Sudo H; Milanga M; Takamizawa H; Fujii S
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2426-35. PubMed ID: 2614181
[TBL] [Abstract][Full Text] [Related]
11. [A basic and clinical study of CA 19-9-MP-Mitsui kit for determination of CA 19-9].
Ishii M; Iida M; Seino Y
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2779-86. PubMed ID: 7993114
[TBL] [Abstract][Full Text] [Related]
12. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen].
Machida T; Ohishi Y; Wada T; Akimoto S; Shimazaki J; Oda H; Yokoyama M; Tsukada T; Nakayama T; Akiyama A
Hinyokika Kiyo; 1993 Oct; 39(10):977-84. PubMed ID: 7505519
[TBL] [Abstract][Full Text] [Related]
14. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
15. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
Miladinović D; Paunović R; Paunković N
Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
[TBL] [Abstract][Full Text] [Related]
16. Sources of variability in normal CA 125 levels.
Westhoff C; Levin B; Ladd G; O'Connor J
Cancer Epidemiol Biomarkers Prev; 1992; 1(5):357-9. PubMed ID: 1305467
[TBL] [Abstract][Full Text] [Related]
17. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
18. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of CA 15-3 radioimmunoassay].
Takemori Y; Odani H; Watanabe H; Ohta H; Satomura Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):114-8. PubMed ID: 3467654
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]